{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:57:31Z","timestamp":1779933451102,"version":"3.53.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.024","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T14:44:51Z","timestamp":1622558691000},"page":"60-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Nose in malignant mesothelioma\u2014Prediction of response to immune checkpoint inhibitor treatment"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-4155","authenticated-orcid":false,"given":"Maria J.","family":"Disselhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-6246","authenticated-orcid":false,"given":"Josine","family":"Quispel-Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Wolf-Lansdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Sterk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-9556","authenticated-orcid":false,"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2021.04.024_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respiratory J"},{"issue":"14","key":"10.1016\/j.ejca.2021.04.024_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10026","key":"10.1016\/j.ejca.2021.04.024_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.024_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.024_bib5","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2021.04.024_bib6","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Canc Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.024_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.024_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Res Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.024_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Res Med"},{"issue":"12","key":"10.1016\/j.ejca.2021.04.024_bib10","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.024_bib11","series-title":"World conference on lung cancer presidential symposium","article-title":"First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743","author":"Baas","year":"2020"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.024_bib12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.024_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Canc"},{"issue":"8","key":"10.1016\/j.ejca.2021.04.024_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.024_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.21037\/tlcr.2018.04.09","article-title":"Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review","volume":"7","author":"Brusselmans","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.024_bib16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1183\/09031936.00040911","article-title":"A breath test for malignant mesothelioma using an electronic nose","volume":"40","author":"Chapman","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.024_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.lungcan.2011.08.009","article-title":"An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls","volume":"75","author":"Dragonieri","year":"2012","journal-title":"Lung Canc"},{"issue":"53","key":"10.1016\/j.ejca.2021.04.024_bib18","doi-asserted-by":"crossref","first-page":"91593","DOI":"10.18632\/oncotarget.21335","article-title":"Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study","volume":"8","author":"Lamote","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.024_bib19","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/aafc77","article-title":"Electronic nose: a non-invasive technology for breath analysis of diabetes and lung cancer patients","volume":"13","author":"Behera","year":"2019","journal-title":"J Breath Res"},{"issue":"3","key":"10.1016\/j.ejca.2021.04.024_bib20","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7155\/8\/3\/034001","article-title":"The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva","volume":"8","author":"Amann","year":"2014","journal-title":"J Breath Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.024_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/metabo5010140","article-title":"Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath","volume":"5","author":"Wilson","year":"2015","journal-title":"Metabolites"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.024_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.molmed.2015.08.001","article-title":"Exhaled molecular fingerprinting in diagnosis and monitoring: validating volatile promises","volume":"21","author":"Boots","year":"2015","journal-title":"Trends Mol Med"},{"issue":"10","key":"10.1016\/j.ejca.2021.04.024_bib23","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/annonc\/mdz279","article-title":"Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath","volume":"30","author":"de Vries","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.024_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.04.024_bib25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.024_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01817-2017","article-title":"Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label","volume":"51","author":"de Vries","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.024_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejca.2021.04.024_bib28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.04.024_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.024_bib30","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.04.024_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.024_bib32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaci.2020.07.022","article-title":"eNose breathprints as composite biomarker for real-time phenotyping of complex respiratory diseases","volume":"146","author":"de Vries","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.024_bib33","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1021\/acsomega.7b02035","article-title":"Detection of lung cancer: concomitant volatile organic compounds and metabolomic profiling of six cancer cell lines of different histological origins","volume":"3","author":"Jia","year":"2018","journal-title":"ACS Omega"},{"issue":"14","key":"10.1016\/j.ejca.2021.04.024_bib34","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2174\/1568026616666151223113540","article-title":"Electronic nose and exhaled breath NMR-based metabolomics applications in airways disease","volume":"16","author":"Santini","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"10.1016\/j.ejca.2021.04.024_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.ejca.2021.04.024_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051262","article-title":"Breath analysis for early detection of malignant pleural mesothelioma: volatile organic compounds (VOCs) determination and possible biochemical pathways","volume":"12","author":"Di Gilio","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2021.04.024_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.isci.2018.12.008","article-title":"Profiling single cancer cells with volatolomics approach","volume":"11","author":"Serasanambati","year":"2019","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.ejca.2021.04.024_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13167-018-0128-8","article-title":"The crucial role of multiomic approach in cancer research and clinically relevant outcomes","volume":"9","author":"Lu","year":"2018","journal-title":"EPMA J"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:32Z","timestamp":1760733092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":38,"alternative-id":["S0959804921002707"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose in malignant mesothelioma\u2014Prediction of response to immune checkpoint inhibitor treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}